
|Videos|August 26, 2021
Part 2: Practical Considerations For Venetoclax in AML
Expert continues discussion on important considerations for the optimal use if venetoclax in patients with AML, such as CYP3A4 and p-glycoprotein drug interactions.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Workforce Preparation for Fall Immunization Season Starts Now
3
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
4
Antibody-Drug Conjugates and HER2 Guidelines Are Reshaping Breast Cancer Treatment
5







































































































